Rapid Communications |
From the Department of Pharmacology and Toxicology, School of Pharmacy, Martin Luther University, Halle (Saale), Germany.
Correspondence to Dr Henning Schröder, School of Pharmacy, Martin Luther University, Wolfgang-Langenbeck-Str. 4, 06099 Halle (Saale), Germany. E-mail schroeder{at}pharmazie.uni-halle.de
| Abstract |
|---|
|
|
|---|
Key Words: aspirin ferritin endothelial cell gene expression antioxidant defense mechanism
| Introduction |
|---|
|
|
|---|
The mechanism responsible for the observed aspirin-induced endothelial protection is unknown. From the data published by Podhaisky et al,6 it appears that cytoprotection by aspirin is a long-term effect that occurs after several hours of pretreatment. Therefore, a possible mechanism might be the induction of genes that protect cells from damage by reactive oxygen species. In recent studies, the induction of ferritin has been shown to provide marked antioxidant cellular protection by rapidly sequestering free cytosolic iron, the crucial catalyst of oxygen-centered radical formation via the Fenton reaction in biological systems.7 8 Thus, ferritin, which until then was thought to function merely as a "housekeeper" iron storage protein, has emerged as a critical and fast-acting endogenous cytoprotectant that plays an important role in cellular antioxidant defense mechanisms.9 10 Our aim, therefore, was to investigate whether ferritin is a potential site of action for aspirin and to characterize the effect of aspirin on the expression of ferritin in endothelial cells.
| Materials and Methods |
|---|
|
|
|---|
Cell Culture
Endothelial cells were maintained and
subcultured in DMEM supplemented with 15% FBS, 100 U/mL penicillin,
and 100 µg/mL streptomycin.11 The cells were
grown in a humidified incubator at 37°C and 5%
CO2.
Ferritin mRNA Analysis
Ferritin mRNA content was analyzed in
endothelial cells grown in 150-mm culture dishes after
treatment with control media or aspirin for 6 hours. Total RNA was
isolated with the RNeasy Total RNA Kit. RNA (40 µg) from each sample
was denatured and fractionated by 1% agarose-formaldehyde gel
electrophoresis. RNA was visualized by ethidium bromide staining,
transferred to nylon membranes, and baked for 0.5 hours at 120°C. The
membranes were hybridized with a random-primed digoxigenin-labeled cDNA
probe for human ferritin H8 or for ß-actin
according to the DIG System user's guide (Boehringer
Mannheim). Afterward, membranes were incubated with the
chemiluminescent substrate CSPD (Boehringer Mannheim) and
exposed to x-ray film for 2 hours. Equal loading of each lane with RNA
was assessed by staining 18S and 28S rRNA with ethidium bromide and by
using ß-actin cDNA. Autoradiographs were quantified by
computer-assisted videodensitometry (Eagle Eye II-system, Stratagene).
Autoradiograms were scanned by densitometry, and the
results were normalized to the ratio of ferritin/ß-actin
hybridization seen in control (untreated) cells.
Ferritin Protein Analysis
Endothelial cells were cultured in 6-well plates
as described above. After a 6-hour incubation with control media,
aspirin, salicylic acid, diclofenac, or indomethacin,
cells were washed and extracted as described
previously.12 13 Desferrioxamine was added to the
cells 30 minutes before aspirin. Protein (100 µg) was applied to
SDS-PAGE. After electrophoresis, protein was transferred to a
nitrocellulose membrane, and a polyclonal antibody to human ferritin
(Sigma) was used to identify ferritin protein content. Antigen-antibody
complexes were visualized with the horseradish peroxidase
chemiluminescence system according to the manufacturer's instructions
(Boehringer Mannheim). Quantification of ferritin induction was
performed using computer-assisted videodensitometry (Eagle Eye
II-system, Stratagene).
Cell Viability Analysis
Endothelial cells were seeded at
2x104 cells per well in 96-well microtiter
plates in 100 µL of media containing 15% FBS. After a 48-hour
incubation at 37°C, cells reached confluence, and aspirin,
apoferritin, or ferritin was added. After a 6-hour incubation, hydrogen
peroxide was added to the cells. Incubation was continued for 20 hours,
followed by a cytotoxicity assay. Cell viability was measured by
staining with crystal violet as previously
described.14 15 16 This
colorimetric test allows assessment of the remaining
viable cells after the incubation procedure. After they were washed
with PBS, cells were fixed with methanol for 10 minutes and then
stained for 10 minutes with a 0.1% crystal violet solution. After 3
washes with tap water, the dye was eluted with 0.1 mol/L trisodium
citrate in 50% ethanol for 10 minutes. Optical density at 630 nm was
measured using a microtiter plate reader (Biotek EL 311s).
| Results |
|---|
|
|
|---|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Using cultured endothelial cells, we observed ferritin
induction by aspirin at therapeutically relevant concentrations being
achieved in plasma during low-dose antithrombotic dosing
regimens.18 19 Earlier studies have reported
inhibitory effects of aspirin on nuclear factor-
B
(NF-
B, a transcription factor)20 21 22 and on
the regulation of genes such as nitric oxide
synthase23 24 but only at rather high
concentrations (2 to 20 mmol/L), which are hardly reached or
maintained in plasma even after anti-inflammatory doses of aspirin.
Therefore, and in contrast to NF-
B or NO synthase, ferritin appears
to be a molecular target of aspirin with a particular potential for
clinical significance. Moreover, ferritin induction by aspirin might
explain earlier observations showing that aspirin is capable of
directly protecting cultured endothelial cells from
oxidant injury.6 Interestingly, aspirin-dependent
endothelial protection reported by Podhaisky et
al6 was most pronounced when toxicity was induced
by exogenous ferrous iron, the main Fenton catalyst of oxygen radical
formation in living cells. From the results of the present
investigation, it seems plausible that by increasing the synthesis of
iron-scavenging ferritin, aspirin may specifically withdraw iron ions
from the site of oxygen radical formation and may thus effectively
interrupt the reaction cascade leading to oxidative stress and tissue
damage. Further support for this hypothesis may be derived from our
observation that exogenous iron-free apoferritin but not iron-loaded
ferritin reduced hydrogen peroxidemediated injury in
endothelial cells, thus mimicking the protective action
of aspirin and demonstrating the antioxidant function of newly
synthesized ferritin under these conditions.
According to our results, the stimulatory effect of aspirin on the expression of ferritin is confined to the translational level. No detectable increase in ferritin mRNA was measured in the presence of aspirin. The main physiological stimulus of ferritin protein synthesis is known to be free intracellular iron, which binds to and inactivates the endogenous repressor of ferritin translation, the iron regulatory protein.25 To determine whether aspirin induction of ferritin is related to this pathway or occurs independent of free iron, we performed experiments using the iron chelator desferrioxamine. Coincubation with desferrioxamine completely abolished ferritin induction by aspirin, suggesting that free cytosolic iron is required for this effect and that aspirin increases ferritin synthesis by interacting with and possibly activating the well-known iron-dependent posttranscriptional upregulation of ferritin.25 Interestingly, the ferritin-inducing effect we report here is specific for aspirin and not elicited by other nonsteroidal anti-inflammatory drugs, such as diclofenac, indomethacin, or salicylate. This finding implies that it is the acetyl group within acetylsalicylic acid that confers the capacity to activate ferritin synthesis and that all other inhibitors of cyclooxygenase tested, including nonacetylated salicylate, do not fulfill the structural requirements necessary to activate ferritin translation. Aspirin has been demonstrated to specifically interact with and show affinity toward iron or iron complexes,6 26 and it is therefore conceivable that aspirin accelerates dissociation of the ferritin repressor protein from ferritin mRNA, thus allowing ferritin translation. Clearly, more research is needed in order to further analyze the molecular mechanisms by which aspirin exerts its ferritin-inducing effect.
On the basis of the outcome of recent clinical studies, an increase in cellular iron levels has been suggested as a coronary risk factor that (via enhancing oxidative stress) promotes atherosclerosis and raises the incidence of myocardial infarction.27 28 29 30 Moreover, elevation of catalytically active iron followed by increased expression of ferritin has been observed in atherosclerotic lesions of patients with coronary heart disease, underlining the in vivo relevance of this antioxidant pathway.9 31 32 There has been dispute about the availability in vivo of uncomplexed iron as a Fenton catalyst for redox-based reactions that induce oxidative stress, and the nature of the pool of nonprotein-bound iron in cells and organelles is ill-defined.33 34 However, recent progress in analytical methods has made possible the detection and quantification of nonprotein-bound iron in biological tissues and fluids, including those of human origin, thus confirming the existence of catalytically active ferrous iron in vivo.35 36 Other in vivo evidence for the relevance of free or loosely bound iron in promoting damage by radical formation comes from studies showing beneficial and tissue protective effects of metal-chelating agents such as desferrioxamine under pathological conditions involving oxidative stress.37 38 In light of our investigations, activation of endogenous iron sequestration could be an important mechanism by which aspirin, in addition to its platelet inhibitory action, protects against myocardial infarction, stroke, and death. Since ferritin is thought to play a broader role in the cellular defense against oxidative injury under inflammatory conditions,9 it is conceivable that increased ferritin expression may also contribute in general to the anti-inflammatory action of aspirin.
In summary, we have demonstrated for the first time that aspirin at therapeutically relevant concentrations is capable of activating the synthesis of ferritin, a protein with cytoprotective and antioxidant properties. Although, on the molecular level, aspirin appeared to enhance iron-dependent ferritin translation, the exact mechanism of aspirin-dependent ferritin induction is not yet fully understood and is currently being investigated in our laboratory. However, with regard to the functional consequences and considering the comparatively low aspirin concentrations required to trigger ferritin synthesis, it can be concluded that this novel antioxidant pathway may significantly contribute to aspirin-induced prevention of endothelial injury in cardiovascular disease, eg, during atherogenesis and other inflammatory processes.
| Acknowledgments |
|---|
Received February 2, 1998; accepted March 26, 1998.
| References |
|---|
|
|
|---|
-mediated cytotoxicity. Naunyn Schmiedebergs
Arch Pharmacol. 1993;347:664666.[Medline]
[Order article via Infotrieve]
-mediated cytotoxicity: possible role for
cyclic GMP and heme oxygenase. J Mol Cell
Cardiol. 1997;29:33053310.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
![]() |
K. Erdmann, N. Grosser, K. Schipporeit, and H. Schroder The ACE Inhibitory Dipeptide Met-Tyr Diminishes Free Radical Formation in Human Endothelial Cells via Induction of Heme Oxygenase-1 and Ferritin J. Nutr., August 1, 2006; 136(8): 2148 - 2152. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kojda Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity? Cardiovasc Res, November 1, 2004; 64(2): 192 - 194. [Full Text] [PDF] |
||||
![]() |
J.L. Mehta, J. Chen, F. Yu, and D.Y. Li Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells Cardiovasc Res, November 1, 2004; 64(2): 243 - 249. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M Wasserman and J. N Topper Adaptation of the endothelium to fluid flow: in vitro analyses of gene expression and in vivo implications Vascular Medicine, February 1, 2004; 9(1): 35 - 45. [Abstract] [PDF] |
||||
![]() |
N. Grosser and H. Schroder Aspirin Protects Endothelial Cells From Oxidant Damage Via the Nitric Oxide-cGMP Pathway Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1345 - 1351. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Oberle, A. Abate, N. Grosser, A. Hemmerle, H. J. Vreman, P. A. Dennery, H. T. Schneider, D. Stalleicken, and H. Schroder Endothelial Protection by Pentaerithrityl Trinitrate: Bilirubin and Carbon Monoxide as Possible Mediators Experimental Biology and Medicine, May 1, 2003; 228(5): 529 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Prasad and P. Lee Suppression of Oxidative Stress as a Mechanism of Reduction of Hypercholesterolemic Atherosclerosis by Aspirin Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 61 - 69. [Abstract] [PDF] |
||||
![]() |
J. De Cristobal, A. Cardenas, I. Lizasoain, J. C. Leza, P. Fernandez-Tome, P. Lorenzo, and M. A. Moro Inhibition of Glutamate Release via Recovery of ATP Levels Accounts for a Neuroprotective Effect of Aspirin in Rat Cortical Neurons Exposed to Oxygen-Glucose Deprivation Stroke, January 1, 2002; 33(1): 261 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Polte, A. Abate, P. A. Dennery, and H. Schroder Heme Oxygenase-1 Is a cGMP-Inducible Endothelial Protein and Mediates the Cytoprotective Action of Nitric Oxide Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1209 - 1215. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Talbodec, N. Berkane, V. Blandin, J. P. Breittmayer, E. Ferrari, C. Frelin, and P. Vigne Aspirin and Sodium Salicylate Inhibit Endothelin ETA Receptors by an Allosteric Type of Mechanism Mol. Pharmacol., April 1, 2000; 57(4): 797 - 804. [Abstract] [Full Text] |
||||
![]() |
T. Stefanec Endothelial Apoptosis: Could It Have a Role in the Pathogenesis and Treatment of Disease? Chest, March 1, 2000; 117(3): 841 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kagawa, H. Azuma, M. Akaike, Y. Kanagawa, and T. Matsumoto Aspirin Reduces Apolipoprotein(a) (Apo(a)) Production in Human Hepatocytes by Suppression of Apo(a) Gene Transcription J. Biol. Chem., November 26, 1999; 274(48): 34111 - 34115. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Hickenbottom, J. C. Grotta, R. Strong, L. A. Denner, J. Aronowski, and R. L. Macdonald Nuclear Factor-{kappa}B and Cell Death After Experimental Intracerebral Hemorrhage in Rats • Editorial Comment Stroke, November 1, 1999; 30 (11): 2472 - 2478. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Stefanec Circulating Apoptotic Endothelial Cells Blood, August 15, 1999; 94(4): 1482 - 1483. [Full Text] [PDF] |
||||
![]() |
B. de Valk and J. J. M. Marx Iron, Atherosclerosis, and Ischemic Heart Disease Arch Intern Med, July 26, 1999; 159(14): 1542 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Wolin Novel Antioxidant Action of Aspirin May Contribute to Its Beneficial Cardiovascular Actions Circ. Res., May 19, 1998; 82(9): 1021 - 1022. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |